Healthcare
Carl Zeiss Meditec AG Unsponsored ADR(CZMWY)
Live Price
Offline$28.41
-0.59% today
1Y Change
-57.44%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $2.36B
- Revenue Growth
- +7.8%
- EPS Growth
- -24.4%
- Dividend Yield
- 2.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Carl Zeiss Meditec AG Unsponsored ADR (CZMWY) is a Healthcare stock with a market cap of $2.36B and listed on OTC. The stock last traded around $28.41 and down 57.4% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +7.8%, EPS growth of -24.4%, a dividend yield of 2.0%. What stands out right now is revenue +7.8%, EPS -24.4%, free cash flow +97.9% with operating margin 13.2% and ROIC 7.7%. The dividend is present but secondary, with a yield around 2.0%. Valuation is more restrained than many high-expectation growth names at P/E 16.7 and price/sales 1.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CZMWY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+7.8% vs +7.6% peer median
Operating Margin
Below sector median
+13.2% vs +19.4% peer median
P/E
Below sector median
16.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +7.8% and EPS is at -24.4%, with operating margin around 13.2%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.0%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -7.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | -12.2% | -13.1% | -12.5% |
2026 May 11, 2026 | โ | +9.5% | -3.4% | -2.8% |
2026 Feb 10, 2026 | โ | -3.3% | -4.5% | -16.8% |
Benchmark Edge
CZMWY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CZMWY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CZMWY Max Drawdown
-60.38%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CZMWY and SPY.
Company Overview
Carl Zeiss Meditec AG Unsponsored ADR
OTC
Carl Zeiss Meditec AG Unsponsored ADR is a financial instrument representing shares of Carl Zeiss Meditec AG, a German company specializing in medical technology. The primary purpose of this Unsponsored American Depositary Receipt (ADR) is to enable US investors to invest in the underlying foreign company without the need to directly purchase shares on non-US exchanges. Carl Zeiss Meditec AG focuses on producing and delivering a wide array of medical solutions, particularly for ophthalmology and microsurgery, offering products such as surgical microscopes, diagnostic instruments, and intraocular lenses. Operating in sectors crucial to healthcare, Carl Zeiss Meditec AG plays a significant role in advancing medical technology and solutions globally. The ADR provides a means for US investors to participate in the company's growth and benefit from its contributions to the medical sector, enhancing market accessibility and diversification.
- Leadership
- Dr. Markus Weber
- Employees
- 4.2k
- Street Address
- Goschwitzer Strasse 51-52
- Mailing
- Jena, 07745
- Region
- Jena, Germany
- Last Updated
- May 11, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 16.7
- EV/EBITDA
- 8.2
- Price/Sales
- 1.1
- Price/Book
- 1.1
Growth
- Revenue
- +7.8%
- EPS
- -24.4%
- Free Cash Flow
- +97.9%
Profitability
- Gross Margin
- 65.8%
- Operating Margin
- 13.2%
- Net Margin
- 6.3%
- ROE
- 6.8%
- ROIC
- 7.7%
Balance Sheet
- Debt/Equity
- 0.29
- Current Ratio
- 2.35
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.